Literature DB >> 17542758

Next generation: tuberculosis vaccines that elicit protective CD8+ T cells.

Samuel M Behar1, Joshua S M Woodworth, Ying Wu.   

Abstract

Tuberculosis continues to cause considerable human morbidity and mortality worldwide, particularly in people coinfected with HIV. The emergence of multidrug resistance makes the medical treatment of tuberculosis even more difficult. Thus, the development of a tuberculosis vaccine is a global health priority. Here we review the data concerning the role of CD8+ T cells in immunity to tuberculosis and consider how CD8+ T cells can be elicited by vaccination. Many immunization strategies have the potential to elicit CD8+ T cells and we critically review the data supporting a role for vaccine-induced CD8+ T cells in protective immunity. The synergy between CD4+ and CD8+ T cells suggests that a vaccine that elicits both T-cell subsets has the best chance at preventing tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542758      PMCID: PMC3134449          DOI: 10.1586/14760584.6.3.441

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  111 in total

1.  A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity.

Authors:  Steven C Derrick; Amy Li Yang; Sheldon L Morris
Journal:  Vaccine       Date:  2004-12-21       Impact factor: 3.641

2.  Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes.

Authors:  J Hess; D Miko; A Catic; V Lehmensiek; D G Russell; S H Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

3.  Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guérin-infected dendritic cells.

Authors:  C Demangel; A G Bean; E Martin; C G Feng; A T Kamath; W J Britton
Journal:  Eur J Immunol       Date:  1999-06       Impact factor: 5.532

4.  Therapy of tuberculosis in mice by DNA vaccination.

Authors:  D B Lowrie; R E Tascon; V L Bonato; V M Lima; L H Faccioli; E Stavropoulos; M J Colston; R G Hewinson; K Moelling; C L Silva
Journal:  Nature       Date:  1999-07-15       Impact factor: 49.962

5.  Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis.

Authors:  A T Kamath; C G Feng; M Macdonald; H Briscoe; W J Britton
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

6.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Authors:  Helen McShane; Ansar A Pathan; Clare R Sander; Sheila M Keating; Sarah C Gilbert; Kris Huygen; Helen A Fletcher; Adrian V S Hill
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

7.  Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.

Authors:  Jun Wang; Lisa Thorson; Richard W Stokes; Michael Santosuosso; Kris Huygen; Anna Zganiacz; Mary Hitt; Zhou Xing
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

8.  Characterization of human Mycobacterium bovis bacille Calmette-Guérin-reactive CD8+ T cells.

Authors:  S M Smith; A S Malin; T Pauline; S E Atkinson; J Content; K Huygen; H M Dockrell
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

9.  Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis.

Authors:  S M Behar; C C Dascher; M J Grusby; C R Wang; M B Brenner
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

Review 10.  Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?

Authors:  Ingo Drexler; Caroline Staib; Gerd Sutter
Journal:  Curr Opin Biotechnol       Date:  2004-12       Impact factor: 9.740

View more
  17 in total

1.  Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.

Authors:  Xindong Teng; Maopeng Tian; Jianrong Li; Songwei Tan; Xuefeng Yuan; Qi Yu; Yukai Jing; Zhiping Zhang; Tingting Yue; Lei Zhou; Xionglin Fan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain.

Authors:  Natalie A Parlane; Katrin Grage; Jason W Lee; Bryce M Buddle; Michel Denis; Bernd H A Rehm
Journal:  Appl Environ Microbiol       Date:  2011-10-07       Impact factor: 4.792

Review 3.  CD8 T cells and Mycobacterium tuberculosis infection.

Authors:  Philana Ling Lin; JoAnne L Flynn
Journal:  Semin Immunopathol       Date:  2015-04-28       Impact factor: 9.623

4.  Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses.

Authors:  Rebecca Axelsson-Robertson; Frank Weichold; Donata Sizemore; Markus Wulf; Yasir A W Skeiky; Jerry Sadoff; Markus J Maeurer
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

5.  Analysis of predicted CD8+ T cell epitopes from proteins encoded by the specific RD regions of Mycobacterium tuberculosis for vaccine development and specific diagnosis.

Authors:  Jiuling Wang; Hongmei Zhang; Honghai Wang
Journal:  Mol Biol Rep       Date:  2009-07-17       Impact factor: 2.316

6.  Mycobacterium tuberculosis-specific CD8+ T cells require perforin to kill target cells and provide protection in vivo.

Authors:  Joshua S Woodworth; Ying Wu; Samuel M Behar
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

7.  Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis.

Authors:  Joseph Hinchey; Bo Y Jeon; Holly Alley; Bing Chen; Michael Goldberg; Steven Derrick; Sheldon Morris; William R Jacobs; Steven A Porcelli; Sunhee Lee
Journal:  PLoS One       Date:  2011-01-10       Impact factor: 3.240

8.  A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice.

Authors:  Pin-Yu Perera; Steven C Derrick; Kristopher Kolibab; Fumiki Momoi; Masafumi Yamamoto; Sheldon L Morris; Thomas A Waldmann; Liyanage P Perera
Journal:  Vaccine       Date:  2009-02-06       Impact factor: 3.641

Review 9.  Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Authors:  Else Marie Agger
Journal:  Adv Drug Deliv Rev       Date:  2015-11-17       Impact factor: 15.470

10.  An unbiased peptide-wide discovery approach to select Mycobacterium tuberculosis antigens that target CD8+ T cell response during infection.

Authors:  Mark J Cayabyab; Lizeng Qin; Suely S Kashino; Angelo Izzo; Antonio Campos-Neto
Journal:  Vaccine       Date:  2013-08-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.